Single Center Experience of Oral Vancomycin Therapy in Young Patients with Primary Sclerosing Cholangitis: A Case Series
Livers · 06.03.2023 · 3 (1) · 93-104
DOI: 10.3390/livers3010009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 06.03.2023. Verfasst von Amala J. Alenchery und 7 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There is no single proven therapy that prolongs hepatic transplant-free survival in patients with primary sclerosing cholangitis (PSC). Oral vancomycin (OV) has shown some benefit in small pediatric and adult series. We describe the effect of OV on pediatric onset PSC at our tertiary hospital. This is a single-center, retrospective, descriptive case series involving patients (
Zitieren
APA
Alenchery, A. J., Patel, S., Mahajan, L., Kurowski, J. A., Worley, S., Hupertz, V., Radhakrishnan, K., & Kabbany, M. N. (2023). Single Center Experience of Oral Vancomycin Therapy in Young Patients with Primary Sclerosing Cholangitis: A Case Series. Livers, 3(1), 93-104. https://doi.org/10.3390/livers3010009
Vancouver
Alenchery AJ, Patel S, Mahajan L, Kurowski JA, Worley S, Hupertz V, et al. Single Center Experience of Oral Vancomycin Therapy in Young Patients with Primary Sclerosing Cholangitis: A Case Series. Livers. 2023;3(1):93-104. doi:10.3390/livers3010009
BibTeX
@article{Alenchery2023,
author = {Alenchery, Amala J. and Patel, Sophia and Mahajan, Lori and Kurowski, Jacob A. and Worley, Sarah and Hupertz, Vera and Radhakrishnan, Kaddakal and Kabbany, Mohammad Nasser},
title = {Single Center Experience of Oral Vancomycin Therapy in Young Patients with Primary Sclerosing Cholangitis: A Case Series},
journal = {Livers},
year = {2023},
volume = {3},
number = {1},
pages = {93--104},
doi = {10.3390/livers3010009}
}
EUVIMED